Contineum Therapeutics, Inc. Class A Financial Overview
Contineum Therapeutics, Inc. Class A's market cap is currently $306.67M. The company's EPS TTM is $-0.45; its P/E ratio is -4.61; Contineum Therapeutics, Inc. Class A is scheduled to report earnings on October 30, 2025, and the estimated EPS forecast is $-0.43. See an overview of income statement, balance sheet, and cash flow financials.
